(IMVT) –
-
Form 4 Immunovant, Inc. For: Apr 17 Filed by: Levine Mark S.
-
Form 4 Immunovant, Inc. For: Apr 17 Filed by: Macias William L.
-
Form 4 Immunovant, Inc. For: Apr 17 Filed by: Barnett Eva Renee
-
Form 4 Immunovant, Inc. For: Apr 17 Filed by: Butchko Julia G.
-
Form 4 Immunovant, Inc. For: Apr 17 Filed by: Salzmann Peter
-
Form S-8 Immunovant, Inc.
-
Form 4 Immunovant, Inc. For: Apr 09 Filed by: Barnett Eva Renee
-
Form 4 Immunovant, Inc. For: Apr 09 Filed by: Butchko Julia G.
-
Form 4 Immunovant, Inc. For: Apr 09 Filed by: Salzmann Peter
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Fromkin Andrew J.
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Hughes Douglas J.
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: MIGAUSKY GEORGE V
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Pande Atul
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Torti Frank
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Stout Jay S
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Levine Mark S.
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Macias William L.
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Geffner Michael
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Butchko Julia G.
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Barnett Eva Renee
-
Form 4 Immunovant, Inc. For: Apr 02 Filed by: Salzmann Peter
-
Oppenheimer Starts Immunovant (IMVT) at Outperform, 'expect the execution to unlock considerable value'
-
Guggenheim reiterates Buy rating on Tourmaline Bio (TRML), "news is likely to increase investors' perceived risk"
-
Immunovant (IMVT) Climbs 23%
-
Roche falls, Argenx (ARGX) gains after Chugai's Enspryng drug for myasthenia gravis fails
-
Top pharma stocks to own in 2024 – Citi
-
Immunovant (IMVT) call put ratio 2 calls to 1 put as share price down 4.1%
-
Goldman Sachs Starts Immunovant (IMVT) at Buy
-
Immunovant (IMVT) Granted US Patent for IMVT-1402
-
Immunovant Awarded U.S. Patent for IMVT-1402
-
Form 4 Immunovant, Inc. For: Feb 22 Filed by: Barnett Eva Renee
-
Form 4 Immunovant, Inc. For: Feb 22 Filed by: Levine Mark S.
-
Form 4 Immunovant, Inc. For: Feb 22 Filed by: Macias William L.
-
Form 4 Immunovant, Inc. For: Feb 22 Filed by: Butchko Julia G.
-
Form 4 Immunovant, Inc. For: Feb 22 Filed by: Salzmann Peter
-
JPMorgan Starts Immunovant (IMVT) at Overweight, 'Pushing the Envelope in the FcRn Race'
-
Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
-
Wolfe Research Starts Immunovant (IMVT) at Outperform
-
Form SC 13G/A Immunovant, Inc. Filed by: Deep Track Capital, LP
-
Immunovant, Inc. (IMVT) Tops Q3 EPS by 7c
-
Form 10-Q Immunovant, Inc. For: Dec 31
-
Form 8-K Immunovant, Inc. For: Feb 12
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
-
Form SC 13G Immunovant, Inc. Filed by: FMR LLC
-
Form 4 Immunovant, Inc. For: Jan 26 Filed by: Levine Mark S.
-
Form 4 Immunovant, Inc. For: Jan 26 Filed by: Geffner Michael
-
Form 4 Immunovant, Inc. For: Jan 18 Filed by: Macias William L.
-
Form 3 Immunovant, Inc. For: Jan 16 Filed by: Geffner Michael
-
Form 4 Immunovant, Inc. For: Jan 11 Filed by: Barnett Eva Renee
-
Form 4 Immunovant, Inc. For: Jan 05 Filed by: Butchko Julia G.
Back to IMVT Stock Lookup